Tempus AI (NASDAQ:TEM) Earns Overweight Rating from Analysts at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of Tempus AI (NASDAQ:TEM) in a research report sent to investors on Wednesday morning, Marketbeat reports. The brokerage issued an overweight rating and a $80.00 target price on the stock.

Other analysts have also recently issued reports about the company. Stifel Nicolaus cut their price objective on Tempus AI from $60.00 to $50.00 and set a “hold” rating for the company in a research report on Monday, August 3rd. Wolfe Research started coverage on Tempus AI in a report on Tuesday, June 2nd. They set a “peer perform” rating on the stock. Lake Street Capital cut Tempus AI to a “hold” rating in a research note on Monday, July 20th. HC Wainwright decreased their price objective on shares of Tempus AI from $64.00 to $56.00 and set a “buy” rating on the stock in a report on Monday, August 3rd. Finally, Weiss Ratings lowered shares of Tempus AI from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 27th. Eleven research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Tempus AI has a consensus rating of “Moderate Buy” and a consensus target price of $68.93.

Tempus AI Stock Performance

Shares of TEM opened at $64.62 on Wednesday. The firm has a market cap of $11.66 billion, a P/E ratio of -44.87 and a beta of 3.72. Tempus AI has a twelve month low of $40.77 and a twelve month high of $104.32. The company has a debt-to-equity ratio of 3.06, a quick ratio of 3.16 and a current ratio of 3.30. The firm’s 50 day moving average price is $55.77 and its two-hundred day moving average price is $52.13.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.10. The company had revenue of $382.49 million during the quarter, compared to analysts’ expectations of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.Tempus AI’s revenue for the quarter was up 21.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.22) earnings per share. On average, analysts forecast that Tempus AI will post -1.38 EPS for the current fiscal year.

Insider Activity

In related news, CEO Eric P. Lefkofsky sold 11,848 shares of the stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $69.87, for a total value of $827,819.76. Following the completion of the transaction, the chief executive officer owned 150,000 shares of the company’s stock, valued at $10,480,500. This represents a 7.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Ryan Fukushima sold 14,286 shares of the stock in a transaction on Friday, August 21st. The shares were sold at an average price of $70.00, for a total value of $1,000,020.00. Following the completion of the transaction, the chief executive officer owned 47,420 shares of the company’s stock, valued at $3,319,400. The trade was a 23.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 1,043,988 shares of company stock valued at $56,963,417. Corporate insiders own 24.26% of the company’s stock.

Institutional Investors Weigh In On Tempus AI

Several large investors have recently modified their holdings of the company. JPL Wealth Management LLC bought a new stake in Tempus AI in the third quarter valued at $26,000. Los Angeles Capital Management LLC bought a new position in shares of Tempus AI during the 4th quarter worth about $27,000. EMC Capital Management bought a new position in shares of Tempus AI during the 2nd quarter worth about $29,000. Harvest Fund Management Co. Ltd acquired a new stake in shares of Tempus AI in the 3rd quarter valued at about $38,000. Finally, Whittier Trust Co. grew its stake in shares of Tempus AI by 190.0% in the 1st quarter. Whittier Trust Co. now owns 870 shares of the company’s stock valued at $41,000 after buying an additional 570 shares during the period. 24.22% of the stock is currently owned by institutional investors and hedge funds.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.